5 completed, 4 terminated, 1 active not recruiting. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Terminated 4, Active not recruiting 1 |
Follow Eosinophilic Asthma: new trials by email Literature Review of Eosinophilic Asthma trials Research Report on Eosinophilic Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment ICS-LABA, benralizumab, Placebo for Benralizumab - Eosinophilic Asthma | Phase 3 | Completed | AstraZeneca | 130 | 2025-03-28 | 2026-10-16 |
| Phase III Long-Term Extension Study With Dexpramipexole Dexpramipexole Dihydrochloride - Eosinophilic Asthma | Phase 3 | Terminated | Areteia Therapeutics | 509 | 2024-06-12 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3) Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 654 | 2023-03-27 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma. Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Terminated | Areteia Therapeutics | 1061 | 2023-01-30 | 2025-12-15 |
| A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma Dexpramipexole Dihydrochloride, Placebo - Eosinophilic Asthma, Asthma; Eosinophilic | Phase 3 | Active not recruiting | Areteia Therapeutics | 600 | 2023-01-30 | 2025-09-05 |
| Study to Evaluate the Efficacy and Safety of Reslizumab Treatment in Patients With Moderate to Severe Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 511 | 2012-02-01 | 2016-06-27 |
| Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma Reslizumab - Eosinophilic Asthma | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 1052 | 2011-06-01 | 2016-06-06 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 489 | 2011-04-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab in Patients With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 464 | 2011-03-01 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma Reslizumab, Placebo - Eosinophilic Asthma | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 315 | 2011-02-01 | 2016-06-06 |
Pulmonary Eosinophilia (10) · Asthma (4)
Eosinophilia (10) · Hematologic Diseases (10) · Hemic and Lymphatic Diseases (10) · Hypereosinophilic Syndrome (10) · Leukocyte Disorders (10) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Bronchial Diseases (4) · Hypersensitivity (4) · Hypersensitivity, Immediate (4) · Immune System Diseases (4) · Lung Diseases, Obstructive (4) · Respiratory Hypersensitivity (4)
Antibodies, Monoclonal, Humanized (5) · reslizumab (5) · benralizumab (1)
Teva Branded Pharmaceutical Products R&D, Inc. (5) · Areteia Therapeutics (4) · AstraZeneca (1)
United States (10) · Argentina (7) · Brazil (7) · Mexico (7) · Canada (6) · Poland (6) · South Korea (6) · Ukraine (6) · France (5) · Israel (5) · Romania (5) · South Africa (5) · United Kingdom (5) · Colombia (4) · Germany (4)
Michael E. Wechsler, MD (1) · Mona Bafadhel, MD (1) · Sady Alpizar, MD (1) · Salman Siddiqui, MD (1)
PMID 39393433, PMID 25736990, PMID 28159511, PMID 30193936, PMID 30346831, PMID 30964365, PMID 31262379, PMID 31626990, PMID 27018175, PMID 27056586
2023 (1)